Do Systemic Alpha-2 Agonists Lower Glaucoma Risk?
A large US cohort study found systemic alpha-2 agonist use was associated with a lower hazard of glaucoma-related diagnoses vs. beta-blockers.
By
Andrea Surnit
July 8, 2026
Clinical Scorecard: Do Systemic Alpha-2 Agonists Lower Glaucoma Risk?
At a Glance
Category Detail
Condition Glaucoma-related diagnoses Key Mechanisms Intraocular pressure modulation and vascular-neuroprotective pathways Target Population Adult patients with hypertension aged 40 years or older Care Setting Multicenter, retrospective cohort study using electronic health records
Key Highlights
Systemic alpha-2 agonists associated with lower odds of ocular hypertension and primary open-angle glaucoma compared to beta-blockers. 2% of alpha-2 agonist users developed primary open-angle glaucoma at 3 years vs. 3% of beta-blocker users. At 5 years, 2% of alpha-2 agonist users vs. 4% of beta-blocker users developed primary open-angle glaucoma. Ocular hypertension rates were lower among alpha-2 agonist users at 5 years (2% vs. 4%). Findings warrant further prospective and mechanistic study. Guideline-Based Recommendations
Diagnosis
Diagnoses based on diagnostic codes; further detailed ophthalmic measures not included. Management
Consider systemic alpha-2 agonists for hypertension management in patients at risk for glaucoma. Monitoring & Follow-up
Monitor for glaucoma-related diagnoses in patients receiving systemic alpha-2 agonists. Risks
Observational study design limits causality; potential for residual confounding. Patient & Prescribing Data
Patients aged 40 years or older with hypertension
Systemic alpha-2 agonists may lower glaucoma risk compared to beta-blockers.
Clinical Best Practices
Further exploration of the association between systemic alpha-2 agonists and glaucoma risk is recommended. Related Resources & Content
